This article is more than 5 years old. Information may no longer be current.
Immuron receives patent claim for NASH treatment development
Immuron announced its patent application for the development of nonalcoholic steatohepatitis treatment methods received a Notice of Allowance from the United States Patent and Trademarks Office, according to a company press release.
“NASH is an interesting disease itself,” Jerry Kanellos, PhD, interim CEO of Immuron, told Healio.com/Hepatology. “Over 30% of the U.S. population is morbidly obese, and really the drivers are the western diet ... 30% to 40% of the population have fatty livers and we’re also seeing this in the pediatric population.”
The application included 10 method-to-treat claims. Immuron currently has three ongoing trials: one trial of IMM-124E for NASH; one trial focused on pediatric nonalcoholic fatty liver disease; and one focused on alcoholic steatohepatitis.
IMM-124E is an oral, three-times daily, non-absorbable compound that contains poly-clonal anti-lipopolysaccharide immunoglobulins.
The IMM-124E study is a phase 2 trial designed to compare two different doses of the compound with placebo. The study currently includes 133 adult patients with NASH. Interim analysis data released this year demonstrated that both 600 mg and 1,200 mg of IMM-124E reduced alanine aminotransferase and aspartate aminotransferase levels in patients compared with placebo.
– by Talitha Bennett
Disclosure: Kanellos is an employee of Immuron.